Context Therapeutics Inc. (NASDAQ:CNTX) Stock Has Average Target Price of $6.40 According to Analysts

Context Therapeutics Inc. (NASDAQ:CNTX) has earned a consensus rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $6.40.

A number of analysts have recently issued reports on the company. Lifesci Capital downgraded Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Zacks Research cut shares of Context Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, October 12th. Wall Street Zen downgraded shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th. Weiss Ratings upgraded shares of Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 15th. Finally, Citigroup reiterated an “outperform” rating on shares of Context Therapeutics in a research report on Thursday, August 6th.

Hedge Funds Weigh In On Context Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. raised its stake in shares of Context Therapeutics by 8,907.7% during the third quarter. Russell Investments Group Ltd. now owns 671,074 shares of the company’s stock valued at $202,000 after acquiring an additional 663,624 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of Context Therapeutics in the second quarter worth approximately $29,000. Two Sigma Securities LLC increased its holdings in Context Therapeutics by 388.7% in the 2nd quarter. Two Sigma Securities LLC now owns 61,444 shares of the company’s stock worth $34,000 after buying an additional 48,871 shares in the last quarter. Bank of America Corp DE bought a new stake in Context Therapeutics in the 2nd quarter worth approximately $30,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Context Therapeutics during the 2nd quarter valued at about $416,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Stock Up 3.0%

Context Therapeutics stock opened at $0.19 on Friday. The stock has a market cap of $17.78 million, a price-to-earnings ratio of -0.40 and a beta of 1.77. The business has a 50-day simple moving average of $0.30 and a 200 day simple moving average of $1.42. Context Therapeutics has a 52 week low of $0.18 and a 52 week high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.06). On average, research analysts anticipate that Context Therapeutics will post -0.45 earnings per share for the current year.

About Context Therapeutics

Context Therapeutics Inc (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens.

Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers.